Fischer Medical Ventures (FISCHER) Fundamentals 2026 — P/E 95.2x, Revenue Analysis | SniperIQ
Fischer Medical Ventures (FISCHER) is a India-listed Healthcare company in Medical - Devices with a market capitalization of ₹2,549 Crore, trading at ₹38.95 on the NSE. This SniperIQ fundamentals page covers Fischer Medical Ventures's valuation (P/E 95.2x, P/B 6.5x), profitability (net margin 10.1%), revenue (₹309 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Fischer Medical Ventures's market cap?
Fischer Medical Ventures (FISCHER) has a market capitalization of approximately ₹2,549 Crore, trading at ₹38.95 on the NSE. Market cap moves with the live share price.
What is Fischer Medical Ventures's P/E ratio?
Fischer Medical Ventures's trailing twelve-month P/E ratio is 95.2x, with a price-to-book (P/B) of 6.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Fischer Medical Ventures?
Fischer Medical Ventures runs a net profit margin of 10.1%, a gross margin of 32.0%, and an operating margin of 13.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fischer Medical Ventures generate?
Fischer Medical Ventures reported revenue of ₹309 Crore for fiscal year 2025, with net income of ₹31 Crore and earnings per share (EPS) of 0.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fischer Medical Ventures pay a dividend?
Fischer Medical Ventures offers a trailing dividend yield of about 0.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Fischer Medical Ventures financially healthy?
Fischer Medical Ventures carries a debt-to-equity ratio of 0.28x and a current ratio of 1.60x, with a market beta of -0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fischer Medical Ventures a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fischer Medical Ventures (FISCHER) the key facts are: market cap ₹2,549 Crore, P/E 95.2x, revenue ₹309 Crore, 52-week range 31.05-124.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Fischer Medical Ventures's full fundamentals live
Get Fischer Medical Ventures's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.